Veracyte Expands Early Access for Genomic Lung Disease Classifier

The 190-gene Envisia classifier combines RNA whole-transcriptome sequencing and machine learning to detect the genomic pattern of usual interstitial pneumonia, a hallmark of IPF, with 88 percent specificity and 70 percent sensitivity. The genomic test is performed on patient samples obtained through transbronchial biopsy, a nonsurgical procedure that is commonly used in lung evaluation. Veracyte recently received a draft Medicare local coverage decision for Envisia through the MolDX program and anticipates that the policy will become final in early 2019.

Source: https://www.genomeweb.com/business-news/veracyte-expands-early-access-genomic-lung-disease-classifier